分子特征应答分类器指导治疗选择可改善类风湿关节炎患者临床疾病活动度
这项前瞻性干预队列研究评估了PrismRA(整合19个基因表达特征和4个临床特征)指导b/tsDMARD选择对RA患者24周CDAI结局的影响。结果表明依据PrismRA结果选择TNFi与非TNFi治疗与更好的CDAI结局相关。
要点
- PrismRA指导b/tsDMARD选择者24周CDAI MID达成率63.0%,外部对照为42.4%(OR 2.31)。
- 82%的PrismRA队列患者研究治疗选择与PrismRA结果一致。
- PrismRA整合19个基因表达特征和4个临床特征评估TNFi应答不足可能性。
核心结论
- 依据PrismRA结果指导TNFi与非TNFi选择,与匹配外部对照相比可获得更好的24周CDAI结局。
研究设计与样本
- 前瞻性干预队列研究,纳入开始b/tsDMARD治疗的RA患者,PrismRA结果提供给风湿科医生并纳入研究治疗选择。
- 外部对照来自风湿科电子健康记录系统,采用倾向评分与PrismRA患者匹配。
- PrismRA队列330例,匹配对照990例,所有患者基线均为中高疾病活动度。
主要发现
- 82%的PrismRA队列患者研究治疗选择与PrismRA结果一致。
- 两队列关键基线患者特征均平衡良好。
关键数值与推荐
- PrismRA纳入19个基因表达特征和4个临床特征,用于评估患者对TNFi应答不足的可能性。
- 主要结局为24周时临床疾病活动指数(CDAI)达到最小重要差异(MID)。
- 缺失数据采用末次观测值结转(LOCF)填补。
临床怎么用
- 在RA患者启动b/tsDMARD前,可考虑使用PrismRA辅助选择TNFi或非TNFi治疗。
- PrismRA结果可提供给风湿科医生并纳入治疗决策,本研究中82%的病例治疗选择与检测结果一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD). METHODS: PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of inadequate response to tumor necrosis factor inhibitor (TNFi). PrismRA was assessed in a prospective, interventional cohort study of patients initiating treatment with a b/tsDMARD. PrismRA results were provided to treating rheumatologists and incorporated into the selection of TNFi vs non-TNFi for study treatment. External comparator patients were identified in a rheumatology provider electronic health records system and matched to PrismRA patients using propensity scores. All patients had moderate-high disease activity at baseline. The primary study outcome was achievement of minimal important difference (MID) in clinical disease activity index (CDAI) at 24 weeks. Last observation carried forward was used to impute missing data. RESULTS: There were 330 PrismRA cohort patients and 990 matched comparator patients. Key baseline patient characteristics were all well-balanced between cohorts. Study treatment selection was consistent with PrismRA results in 82% of PrismRA cohort patients. CDAI MID at 24 weeks was achieved by 63.0% of PrismRA patients and 42.4% of comparator patients (odds ratio 2.31, confidence interval 1.79-2.99). CONCLUSION: PrismRA results informing selection of TNFi vs non-TNFi treatment was associated with better CDAI outcomes compared to matched external comparator patients. PrismRA testing helps fill the need for a precision medicine approach to more rapidly identify the most effective therapy for individual patients with RA.
引用
- Xie F, Beukelman T, McCormick NP, et al. Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug. Arthritis Care Res (Hoboken). 2026. PMID: 41568556. doi:10.1002/acr.80010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。